Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy
ConclusionsEculizumab appears to be a potential treatment for patients with crescentic rapidly progressive C3 glomerulopathy. Its benefit in patients with non–rapidly progressing forms seems to be limited.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: Canada Health | Children | Chronic Kidney Disease | Databases & Libraries | Dialysis | France Health | Genetics | Nephrotic Syndrome | Pediatrics | Proteinuria | Study | Urology & Nephrology